Boryung Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boryung Pharmaceutical Co., Ltd.
Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.
Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.